Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30366253 | 0.98 | CHRNB2 (0.50) | CHRNB2CHRNA4PIM1CYP11B2DRD2 | |
| Hydrochloric Acid SCHEMBL1583256 | 0.98 | CHRNB2 (0.50) | CHRNB2CHRNA4PIM1CYP11B2DRD2 | |
| SCHEMBL5767402 | 0.80 | ADRB2 (0.52) | PIM1DRD2ALDH1A1 | |
| SCHEMBL3778218 | 0.80 | CHRNB2 (0.51) | CHRNB2CHRNA4CYP11B2DRD2HDAC1 | |
| SCHEMBL532873 | 0.80 | NPC1 (0.50) | GAAMAPTHTT | |
| Hydrochloric Acid SCHEMBL1583646 | 0.79 | ADRB2 (0.50) | PIM1DRD2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2854834 | 0.78 | SLC6A2 (0.49) | GAAMAPTHTT | |
| SCHEMBL22797004 | 0.78 | CYP11B2 (0.54) | CHRNB2CHRNA4CYP11B2DRD2HDAC1 | |
| SCHEMBL255543 | 0.77 | SLC6A2 (0.43) | CHRNB2CHRNA4PIM1DRD3 | |
| SCHEMBL306879 | 0.76 | GAA (0.58) | CHRNB2CHRNA4PIM1CYP11B2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144887-B2 | Substituted 1,2,3-triazolo[1,5-a]quinazolines for enhancing cognition | MERCK SHARP & DOHME LTD. (GB) | 2006-12-05 | — | — | US | disclosed |
| EP-1286967-B1 | CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME (GB) | 2006-09-27 | — | — | EP | disclosed |
| US-7105507-B2 | Cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| US-20050261285-A1 | Tetrahydropyran derivatives and their use as therapeutic agents | DIRAT OLIVIER | 2005-11-24 | — | — | US | disclosed |
| EP-1527062-A1 | TETRAHYDROPYRAN DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004009573-A1 | TETRAHYDROPYRAN DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-01-29 | — | — | WO | disclosed |
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2003-12-25 | — | — | US | disclosed |
| US-20030125333-A1 | Substituted 1,2,3-triazolo[1,5-a]quinazolines for enhancing cognition | MERCK SHARP & DOHME LTD. (GB) | 2003-07-03 | — | — | US | disclosed |
| EP-1286967-A1 | CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 2003-03-05 | — | — | EP | disclosed |
| EP-1242423-A1 | SUBSTITUTED 1,2,3-TRIAZOLO 1,5-a]QUINAZOLINES FOR ENHANCING COGNITION | MERCK SHARP & DOHME LTD. (GB) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001087838-A1 | CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001044250-A1 | SUBSTITUTED 1,2,3-TRIAZOLO[1,5-a]QUINAZOLINES FOR ENHANCING COGNITION | MERCK SHARP & DOHME LIMITED (GB) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | CNR2, CNR1, HTR1A | CHRNB2 542/4885CHRNA4 434/4885PIM1 4219/4885 |
| US-20030125333-A1 | Substituted 1,2,3-triazolo[1,5-a]quinazolines for enhancing cognition | HAX1, HTR1D, CHRM1 | CHRNB2 117/4885CHRNA4 47/4885PIM1 3549/4885 |
| US-20050261285-A1 | Tetrahydropyran derivatives and their use as therapeutic agents | GRPR, GRM5, GRM6 | CHRNB2 2038/4885CHRNA4 912/4885PIM1 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.